Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Sell
39
ALBT Quote, Financials, Valuation and Earnings
Last price:
$3.42
Seasonality move
:
-12.36%
Day range:
$3.36 - $4.10
52-week range:
$2.11 - $21.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.05x
P/B ratio:
--
Volume:
42.4K
Avg. volume:
1.8M
1-year change:
-53.56%
Market cap:
$3.7M
Revenue:
$1.3M
EPS (TTM):
-$19.98
Analysts' Opinion
-
Consensus RatingAvalon Globocare has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Avalon Globocare has an estimated downside of -- from its current price of $3.42.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $3.42.
Fair Value
-
According to the consensus of 0 analysts, Avalon Globocare has -- downside to fair value with a price target of -- per share.
ALBT vs. S&P 500
-
Over the past 5 trading days, Avalon Globocare has underperformed the S&P 500 by -24.15% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Avalon Globocare does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avalon Globocare has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Avalon Globocare reported revenues of $345.2K.
Earnings Growth
-
Avalon Globocare has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Avalon Globocare reported earnings per share of -$1.82.
Enterprise value:
31.4M
EV / Invested capital:
2.23x
Price / LTM sales:
2.05x
EV / EBIT:
--
EV / Revenue:
23.98x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-6.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$279.3K
Return On Assets:
-67%
Net Income Margin (TTM):
-1125.62%
Return On Equity:
-183.88%
Return On Invested Capital:
-90.34%
Operating Margin:
-238.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.2M | $1.2M | $1.3M | $331.3K | $345.2K | |
| Gross Profit | $326.4K | $196.6K | $279.3K | $43.2K | $99.6K | |
| Operating Income | -$7.5M | -$8.6M | -$3.8M | -$1.5M | -$822.1K | |
| EBITDA | -$7.9M | -$8.2M | -$12.1M | -$974.4K | -$1.1M | |
| Diluted EPS | -$19.35 | -$14.06 | -$19.98 | -$2.06 | -$1.82 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2M | $1.3M | $4.4M | $864K | $1.4M | |
| Total Assets | $11.2M | $10.4M | $12.9M | $30M | $19.6M | |
| Current Liabilities | $2.4M | $4.5M | $3.3M | $6.7M | $12.3M | |
| Total Liabilities | $5.8M | $8.5M | $8.3M | $13.1M | $14.1M | |
| Total Equity | $5.3M | $1.9M | $4.6M | $16.8M | $5.4M | |
| Total Debt | $3.3M | $4.4M | $4.6M | $7.9M | $8.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.8M | -$7.7M | -$4.7M | -$1.3M | -$1.9M | |
| Cash From Investing | -$54.9K | -$9M | -$100K | $30 | -- | |
| Cash From Financing | $10.3M | $13.1M | $5.5M | $1M | $2.7M | |
| Free Cash Flow | -$6.8M | -$16.7M | -$4.7M | -$1.3M | -$1.9M | |
ALBT
Sector
Market Cap
$3.7M
$1.1B
Price % of 52-Week High
15.83%
82.88%
Dividend Yield
0%
3.41%
Shareholder Yield
--
3.4%
1-Year Price Total Return
-53.56%
-3.52%
Beta (5-Year)
0.274
0.877
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.89
200-day SMA
Sell
Level
$4.66
Bollinger Bands (100)
Sell
Level
2.73 - 4.51
Chaikin Money Flow
Sell
Level
-115.7M
20-day SMA
Buy
Level
$3.35
Relative Strength Index (RSI14)
Sell
Level
50.00
ADX Line
Buy
Level
31.15
Williams %R
Neutral
Level
-74.8804
50-day SMA
Buy
Level
$3.20
MACD (12, 26)
Buy
Level
0.16
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
172.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.0221)
Sell
CA Score
(Annual)
Level (-4.0605)
Buy
Beneish M-Score
(Annual)
Level (-4.6815)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (8.2047)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Stock Forecast FAQ
In the current month, ALBT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ALBT average analyst price target in the past 3 months is --.
-
Where Will Avalon Globocare Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avalon Globocare share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Avalon Globocare?
Analysts are divided on their view about Avalon Globocare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avalon Globocare is a Sell and believe this share price will rise from its current level to --.
-
What Is Avalon Globocare's Price Target?
The price target for Avalon Globocare over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ALBT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avalon Globocare is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALBT?
You can purchase shares of Avalon Globocare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avalon Globocare shares.
-
What Is The Avalon Globocare Share Price Today?
Avalon Globocare was last trading at $3.42 per share. This represents the most recent stock quote for Avalon Globocare. Yesterday, Avalon Globocare closed at $3.42 per share.
-
How To Buy Avalon Globocare Stock Online?
In order to purchase Avalon Globocare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
